Status of targeted therapies in the adjuvant treatment of colon cancer

Valerie M. Nelson, Al B Benson III

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Colon cancer is the 4th most common malignancy with 80% of patients diagnosed with early stage disease that is potentially curable with surgery and the addition of adjuvant chemotherapy in select Stage II and all Stage III patients. Adjuvant chemotherapy with 5-flurouracil based regimens has been shown to have overall survival benefit in Stage III disease with some benefit shown in certain sub-populations in Stage II disease. In recent years, targeted therapies directed against vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EFGR) have shown improved survival in metastatic colon cancer. However, trials of these agents in the adjuvant setting showed no benefit. Reasons for failure of these agents in trials thus far include differences in the molecular biology of macrometastatic versus micrometastatic disease and the lack of biologic predictive markers to target the appropriate patient populations for these agents.

Original languageEnglish (US)
Pages (from-to)245-252
Number of pages8
JournalJournal of Gastrointestinal Oncology
Volume4
Issue number3
DOIs
StatePublished - Jan 1 2013

Fingerprint

Colonic Neoplasms
Adjuvant Chemotherapy
Survival
Proxy
Therapeutics
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Population
Molecular Biology
Biomarkers
Neoplasms

Keywords

  • Adjuvant therapy
  • Bevacizumab
  • Cetuximab
  • Colon cancer

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

@article{4932d66dc473442abd6cd43c8915a7b4,
title = "Status of targeted therapies in the adjuvant treatment of colon cancer",
abstract = "Colon cancer is the 4th most common malignancy with 80{\%} of patients diagnosed with early stage disease that is potentially curable with surgery and the addition of adjuvant chemotherapy in select Stage II and all Stage III patients. Adjuvant chemotherapy with 5-flurouracil based regimens has been shown to have overall survival benefit in Stage III disease with some benefit shown in certain sub-populations in Stage II disease. In recent years, targeted therapies directed against vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EFGR) have shown improved survival in metastatic colon cancer. However, trials of these agents in the adjuvant setting showed no benefit. Reasons for failure of these agents in trials thus far include differences in the molecular biology of macrometastatic versus micrometastatic disease and the lack of biologic predictive markers to target the appropriate patient populations for these agents.",
keywords = "Adjuvant therapy, Bevacizumab, Cetuximab, Colon cancer",
author = "Nelson, {Valerie M.} and {Benson III}, {Al B}",
year = "2013",
month = "1",
day = "1",
doi = "10.3978/j.issn.2078-6891.2013.035",
language = "English (US)",
volume = "4",
pages = "245--252",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "3",

}

Status of targeted therapies in the adjuvant treatment of colon cancer. / Nelson, Valerie M.; Benson III, Al B.

In: Journal of Gastrointestinal Oncology, Vol. 4, No. 3, 01.01.2013, p. 245-252.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Status of targeted therapies in the adjuvant treatment of colon cancer

AU - Nelson, Valerie M.

AU - Benson III, Al B

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Colon cancer is the 4th most common malignancy with 80% of patients diagnosed with early stage disease that is potentially curable with surgery and the addition of adjuvant chemotherapy in select Stage II and all Stage III patients. Adjuvant chemotherapy with 5-flurouracil based regimens has been shown to have overall survival benefit in Stage III disease with some benefit shown in certain sub-populations in Stage II disease. In recent years, targeted therapies directed against vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EFGR) have shown improved survival in metastatic colon cancer. However, trials of these agents in the adjuvant setting showed no benefit. Reasons for failure of these agents in trials thus far include differences in the molecular biology of macrometastatic versus micrometastatic disease and the lack of biologic predictive markers to target the appropriate patient populations for these agents.

AB - Colon cancer is the 4th most common malignancy with 80% of patients diagnosed with early stage disease that is potentially curable with surgery and the addition of adjuvant chemotherapy in select Stage II and all Stage III patients. Adjuvant chemotherapy with 5-flurouracil based regimens has been shown to have overall survival benefit in Stage III disease with some benefit shown in certain sub-populations in Stage II disease. In recent years, targeted therapies directed against vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EFGR) have shown improved survival in metastatic colon cancer. However, trials of these agents in the adjuvant setting showed no benefit. Reasons for failure of these agents in trials thus far include differences in the molecular biology of macrometastatic versus micrometastatic disease and the lack of biologic predictive markers to target the appropriate patient populations for these agents.

KW - Adjuvant therapy

KW - Bevacizumab

KW - Cetuximab

KW - Colon cancer

UR - http://www.scopus.com/inward/record.url?scp=84995792530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995792530&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2013.035

DO - 10.3978/j.issn.2078-6891.2013.035

M3 - Article

VL - 4

SP - 245

EP - 252

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 3

ER -